Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Polycystic Ovary Syndrome 3Leukoplakia, Oral 2Insulin Resistance 2Glioblastoma 2Erythroplasia 2Endometrial Neoplasms 2Endometrial Hyperplasia 2Carcinoma, Intraductal, Noninfiltrating 2Urothelial Cancer 1Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Prediabetic State 1Pancreatic Adenocarcinoma 1Mouth Neoplasms 1Monoclonal Gammopathy of Undetermined Significance 1Metabolic Diseases 1Lung Neoplasms 1Infertility 1Hyperplasia 1Diabetes Mellitus 1Breast Neoplasms 1Breast Carcinoma In Situ 1Advanced Solid Malignancies 1Advanced Pancreatic Cancer 1

Interventions

Lenalidomide 6carfilzomib 3Dexamethasone 3daratumumab 2Melphalan 2Leflunomide 2poly ICLC 1pembrolizumab 1isatuximab 1fludarabine phosphate 1fludarabine 1citarinostat 1Watchful Waiting 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1PVX-410 vaccine 1Observation 1Myelography 1Metformin 1Cyclophosphamide 1Cholestyramine Resin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Smoldering Multiple Myeloma × Metformin × Clear all
NCT04850846 2026-02-09

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
60 enrolled 10 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡